Saint Joseph's Regional Medical Center

Summary

Saint Joseph's Regional Medical Center is a medical facility located in Paterson, New Jersey. This center is recognized for care of Leukemia, Acute Lymphoblastic Leukemia, Brain Tumor, Lymphoma, Neuroblastoma and other specialties. Saint Joseph's Regional Medical Center is involved with conducting 210 clinical trials across 342 conditions. There are 2 research doctors associated with this hospital, such as Alissa Kahn and Mehandar Kumar.

Top PIs

Clinical Trials running at Saint Joseph's Regional Medical Center

Brain Tumor

Testicular cancer

Burkitt Lymphoma

Leukemia

Neuroblastoma

Acute Lymphoblastic Leukemia

Breast Cancer

Biphenotypic Leukemia

Acute Leukemia

Ovarian Carcinoma

Lower Radiotherapy Dose

for Brain Tumors

This phase II trial studies how well lower dose radiotherapy after chemotherapy (Carboplatin \& Etoposide) works in treating children with central nervous system (CNS) germinomas. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Etoposide is in a class of medications known as podophyllotoxin derivatives. It blocks a certain enzyme needed for cell division and DNA repair and may kill cancer cells. Researchers want to see if lowering the dose of standard radiotherapy (RT) after chemotherapy can help get rid of CNS germinomas with fewer long-term side effects.

Recruiting

1 award

Phase 2

10 criteria

Chemotherapy + Radiation Therapy

for Brain Cancer

This phase II trial studies the best approach to combine chemotherapy and radiation therapy (RT) based on the patient's response to induction chemotherapy in patients with non-germinomatous germ cell tumors (NGGCT) that have not spread to other parts of the brain or body (localized). This study has 2 goals: 1) optimizing radiation for patients who respond well to induction chemotherapy to diminish spinal cord relapses, 2) utilizing higher dose chemotherapy followed by conventional RT in patients who did not respond to induction chemotherapy. Chemotherapy drugs, such as carboplatin, etoposide, ifosfamide, and thiotepa, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy x-rays or high-energy protons to kill tumor cells and shrink tumors. Studies have shown that patients with newly-diagnosed localized NGGCT, whose disease responds well to chemotherapy before receiving radiation therapy, are more likely to be free of the disease for a longer time than are patients for whom the chemotherapy does not efficiently eliminate or reduce the size of the tumor. The purpose of this study is to see how well the tumors respond to induction chemotherapy to decide what treatment to give next. Some patients will be given RT to the spine and a portion of the brain. Others will be given high dose chemotherapy and a stem cell transplant before RT to the whole brain and spine. Giving treatment based on the response to induction chemotherapy may lower the side effects of radiation in some patients and adjust the therapy to a more efficient one for other patients with localized NGGCT.

Recruiting

1 award

Phase 2

Health Information Collection

for Childhood Cancer

This study gathers health information for the Project: Every Child for younger patients with cancer. Gathering health information over time from younger patients with cancer may help doctors find better methods of treatment and on-going care.

Recruiting

1 award

N/A

10 criteria